Clinical Trials Browser

Phase 1/2 × efineptakin alfa × Dermatologic × Clear all

NCT03901573 2025-10-22

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Phase 1/2 Terminated

31 enrolled 12 charts

Melanoma, Carcinoma, Merkel Cell